Abstract Evidence suggests that the JAK2 V617F mutationis associated with an increased risk of first thrombosisin patients with essential thrombocythemia (ET). Whetherthis mutation is also a risk factor for recurrent thrombosis iscurrently unknown. To investigate the impact of the JAK2V617F mutation on the risk of recurrent thrombosis inpatients with ET, we carried out a multicentre retrospectivecohort study. We recruited 143 patients with previousarterial (64.4%) or venous major thrombosis (34.8%) orboth (0.8%); 98 of them (68.5%) carried the mutation

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

CACCIOLA RR;CACCIOLA E;
2010

Abstract

Abstract Evidence suggests that the JAK2 V617F mutationis associated with an increased risk of first thrombosisin patients with essential thrombocythemia (ET). Whetherthis mutation is also a risk factor for recurrent thrombosis iscurrently unknown. To investigate the impact of the JAK2V617F mutation on the risk of recurrent thrombosis inpatients with ET, we carried out a multicentre retrospectivecohort study. We recruited 143 patients with previousarterial (64.4%) or venous major thrombosis (34.8%) orboth (0.8%); 98 of them (68.5%) carried the mutation
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/20.500.11769/53083
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 27
social impact